Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Larry D. Dillon"'
Autor:
Larry D. Dillon, Michael McPhee, Robert S. Davidson, Ann P. Quick, Brian Martin, Kyle R. Covington, Olga Zolochevska, Robert W. Cook, John T. Vetto, Abel D. Jarell, Martin D. Fleming
Publikováno v:
Current Medical Research and Opinion. 38:1267-1274
National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma (CM) recommend physicians consider increased surveillance for patients who typically have lower melanoma survival rates (stages IIB-IV as determined by the American Joint
Autor:
Robert W. Cook, Briana B Rackley, Basil Skenderis, Ann P. Quick, Kelsey Dillon, Brian Martin, Jennifer J Siegel, Abel D Jarell, Larry D Dillon
Publikováno v:
Future oncology (London, England). 17(36)
Aim: Sentinel node biopsy is a prognostic indicator of melanoma recurrence. We hypothesized that adding the primary melanoma molecular signature from the 31-gene expression profile (31-GEP) test could refine the risk of recurrence prognosis for patie
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB116
Autor:
Pedram Gerami, Federico A Monzon, Brian R. Gastman, Xin Huang, Robert W. Cook, Preston Hewgley, Eddy C. Hsueh, Andrew M. Fleming, Adam C. Berger, Jeffrey D. Wayne, Martin D. Fleming, Larry D Dillon, Jennifer Keller, Sancy A. Leachman, John T. Vetto
Publikováno v:
Future Oncology. 15:1207-1217
Aim: Can gene expression profiling be used to identify patients with T1–T2 melanoma at low risk for sentinel lymph node (SLN) positivity? Patients & methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test
Autor:
Joseph E Gadzia, Clare Johnson, Federico A Monzon, John T. Vetto, Eric D Milanese, Abel D Jarell, Michael McPhee, Robert W. Cook, Martin D. Fleming, Larry D Dillon, Robert S. Davidson, Kyle R. Covington
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 2:111-121
Objective: A 31-gene expression profile (GEP) test that has been clinically validated identifies melanoma patients with low (Class 1) or high (Class 2) risk of metastasis based on primary tumor biology. This study aimed to prospectively evaluate the
Autor:
Larry D Dillon, Kyle R. Covington, Clare Johnson, Martin D. Fleming, Joseph E Gadzia, Federico A Monzon
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 1:s107
not available. Disclosures: Study supported by Castle Biosciences, Inc. Copyright SKIN 2018
Autor:
Dillon LD; Larry D. Dillon Surgical Oncology and General Surgery, Colorado Springs, CO, USA., McPhee M; Breast Cancer Program, Advent Health Cancer Institute, Orlando, FL, USA., Davidson RS; Department of Surgical Oncology, Morton Plant Mease Healthcare, FL, USA., Quick AP; Castle Biosciences, Inc, Friendswood, TX, USA., Martin B; Castle Biosciences, Inc, Friendswood, TX, USA., Covington KR; Castle Biosciences, Inc, Friendswood, TX, USA., Zolochevska O; Castle Biosciences, Inc, Friendswood, TX, USA., Cook RW; Castle Biosciences, Inc, Friendswood, TX, USA., Vetto JT; Department of Neurology, Surgical Oncology, Oregon Health & Science University, Portland, OR, USA., Jarell AD; Department of Dermatology, Northeast Dermatology Associates, P.C., Portsmouth, NH, USA., Fleming MD; Department of Surgical Oncology, The University of Tennessee Health Science Center, Memphis, TN, USA.
Publikováno v:
Current medical research and opinion [Curr Med Res Opin] 2022 Aug; Vol. 38 (8), pp. 1267-1274. Date of Electronic Publication: 2022 Feb 15.
Autor:
Vetto JT; Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA., Hsueh EC; Department of Surgery, St Louis University, St Louis, MO 63110, USA., Gastman BR; Department of Plastic Surgery, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44915, USA., Dillon LD; Larry D Dillon Surgical Oncology & General Surgery, Colorado Springs, CO 80907, USA., Monzon FA; Castle Biosciences, Inc., Friendswood, TX 77546, USA., Cook RW; Castle Biosciences, Inc., Friendswood, TX 77546, USA., Keller J; Department of Surgery, St Louis University, St Louis, MO 63110, USA., Huang X; Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA., Fleming A; Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA., Hewgley P; Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA., Gerami P; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago IL 60611, USA.; Skin Cancer Institute, Northwestern University, Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago IL 60611, USA., Leachman S; Department of Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA., Wayne JD; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago IL 60611, USA.; Skin Cancer Institute, Northwestern University, Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA.; Department of Surgical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA., Berger AC; Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19017, USA., Fleming MD; Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2019 Apr; Vol. 15 (11), pp. 1207-1217. Date of Electronic Publication: 2019 Jan 29.